FGL1
FGL1 (fibrinogen like 1, also known as HFREP-1 or HPS) is a secreted, fibrinogen-related protein that suppresses immune responses by acting as a ligand of LAG3. It is also secreted by hepatocytes and promotes their growth. Browse Assay Genie's current range of FGL1 research reagents below, or read on for the biology behind the target.
FGL1 is an immune suppressive molecule that inhibits antigen-specific T-cell activation. It does this by acting as a ligand of LAG3. Binding of FGL1 to LAG3 initiates a signal that inhibits the T-cell receptor (TCR) in the immunological synapse, which prevents T-cell activation. FGL1 binds LAG3 independently of MHC class II (MHC-II), so it is a distinct route to LAG3 engagement from the canonical MHC-II interaction. This makes the FGL1 protein a point of interest in studies of LAG3 signalling and T-cell regulation.
The FGL1 gene encodes a secreted protein and belongs to the fibrinogen C domain containing group. The protein is homologous to the carboxy terminus of the fibrinogen beta and gamma subunits, including the four conserved cysteines found in fibrinogens and fibrinogen-related proteins. It lacks the platelet-binding site, the cross-linking region and the thrombin-sensitive site needed for fibrin clot formation, so it does not behave as a clotting factor. Four alternatively spliced transcript variants are known, and all encode the same protein. Mouse and rat orthologs, both named Fgl1, have been annotated.
FGL1 is secreted by hepatocytes and promotes their growth. The NCBI Gene summary notes that it may play a role in the development of hepatocellular carcinomas. Alternative names include HFREP-1 and HPS. Together, its roles in immune suppression and in liver cell biology make FGL1 a useful target for researchers working on immune checkpoints, tumour immunology and hepatic disease. Studies often consider it alongside the related fibrinogen-like protein FGL2.
FGL1 engages LAG3 to inhibit T-cell receptor signalling, so it is studied as a ligand that restrains T-cell activation.
FGL1 inhibits antigen-specific T-cell activation at the immunological synapse, providing a way to examine LAG3-mediated suppression.
FGL1 may play a role in the development of hepatocellular carcinomas, making it relevant to liver cancer research.
FGL1 is secreted by hepatocytes and promotes their growth, linking it to studies of liver cell proliferation.
FGL1 is an immune suppressive molecule. It acts as a ligand of LAG3, and this binding initiates signalling that inhibits the T-cell receptor in the immunological synapse, preventing T-cell activation. It is also secreted by hepatocytes and promotes their growth.
FGL1 is also known as HFREP-1 and HPS, and its full name is fibrinogen like 1. UniProt names it fibrinogen-like protein 1. Four alternatively spliced transcript variants exist, but according to NCBI Gene they all encode the same protein.
Although FGL1 resembles the C-terminus of fibrinogen beta and gamma, it lacks the platelet-binding site, cross-linking region and thrombin-sensitive site needed for clot formation. It may play a role in hepatocellular carcinoma development. Check the datasheet of any product for its validated reactivity.
Other fibrinogen-like proteins and immune checkpoint partners of FGL1 with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q08830; product specifications from Assay Genie datasheets.